Division of Plastic and Reconstructive Surgery, Washington University School of Medicine, Saint Louis, MO, USA.
Exp Neurol. 2010 Oct;225(2):310-9. doi: 10.1016/j.expneurol.2010.07.001. Epub 2010 Jul 12.
Host Schwann cell (SC) migration into nerve allografts is the limiting factor in the duration of immunosuppression following peripheral nerve allotransplantation, and may be affected by different immunosuppressive regimens. Our objective was to compare SC migration patterns between clinical and experimental immunosuppression regimens both over time and at the harvest endpoint. Eighty mice that express GFP under the control of the Schwann cell specific S100 promoter were engrafted with allogeneic, nonfluorescent sciatic nerve grafts. Mice received immunosuppression with either tacrolimus (FK506), or experimental T-cell triple costimulation blockade (CSB), consisting of CTLA4-immunoglobulin fusion protein, anti-CD40 monoclonal antibody, and anti-inducible costimulator monoclonal antibody. Migration of GFP-expressing host SCs into wild-type allografts was assessed in vivo every 3 weeks until 15 weeks postoperatively, and explanted allografts were evaluated for immunohistochemical staining patterns to differentiate graft from host SCs. Immunosuppression with tacrolimus exhibited a plateau of SC migration, characterized by significant early migration (< 3 weeks) followed by a constant level of host SCs in the graft (15 weeks). At the endpoint, graft fluorescence was decreased relative to surrounding host nerve, and donor SCs persisted within the graft. CSB-treated mice displayed gradually increasing migration of host SCs into the graft, without the plateau noted in tacrolimus-treated mice, and also maintained a population of donor SCs at the 15-week endpoint. SC migration patterns are affected by immunosuppressant choice, particularly in the immediate postoperative period, and the use of a single treatment of CSB may allow for gradual population of nerve allografts with host SCs.
施万细胞(Schwann cell,SC)向神经同种异体移植物中的迁移是周围神经同种异体移植后免疫抑制持续时间的限制因素,并且可能受到不同免疫抑制方案的影响。我们的目的是比较临床和实验性免疫抑制方案中 SC 迁移模式,包括随时间和收获终点的变化。将表达 GFP 的 80 只 GFP 在 Schwann 细胞特异性 S100 启动子控制下表达的 GFP 表达的小鼠进行同种异体、非荧光坐骨神经移植物移植。用他克莫司(FK506)或实验性 T 细胞三协同刺激阻断(CSB)进行免疫抑制,CSB 由 CTLA4-免疫球蛋白融合蛋白、抗 CD40 单克隆抗体和抗诱导共刺激分子单克隆抗体组成。在术后 15 周内,每隔 3 周评估体内 GFP 表达的宿主 SC 向野生型同种异体移植物的迁移情况,并对同种异体移植物进行免疫组织化学染色模式评估,以区分移植物和宿主 SC。他克莫司免疫抑制表现出 SC 迁移的平台期,其特征是早期显著迁移(<3 周),随后在移植物中宿主 SC 保持稳定水平(15 周)。在终点时,与周围宿主神经相比,移植物荧光减少,供体 SC 保留在移植物内。CSB 治疗的小鼠显示宿主 SC 逐渐向移植物中迁移,没有他克莫司治疗小鼠中观察到的平台期,并且在 15 周终点时还维持供体 SC 的群体。SC 迁移模式受免疫抑制剂选择的影响,特别是在术后早期,并且单一使用 CSB 治疗可能允许宿主 SC 逐渐填充神经同种异体移植物。